Compare UFCS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFCS | DRUG |
|---|---|---|
| Founded | 1946 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 933.8M | 856.4M |
| IPO Year | N/A | N/A |
| Metric | UFCS | DRUG |
|---|---|---|
| Price | $34.38 | $87.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $37.50 | ★ $106.75 |
| AVG Volume (30 Days) | 94.8K | ★ 274.2K |
| Earning Date | 02-10-2026 | 02-13-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | ★ 118.04 | N/A |
| EPS | ★ 4.24 | N/A |
| Revenue | ★ $1,353,781,000.00 | N/A |
| Revenue This Year | $10.11 | N/A |
| Revenue Next Year | $3.33 | N/A |
| P/E Ratio | $8.11 | ★ N/A |
| Revenue Growth | ★ 12.12 | N/A |
| 52 Week Low | $24.11 | $23.18 |
| 52 Week High | $37.91 | $123.75 |
| Indicator | UFCS | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 52.90 |
| Support Level | $34.85 | $81.72 |
| Resistance Level | $35.69 | $91.00 |
| Average True Range (ATR) | 0.91 | 8.52 |
| MACD | -0.16 | -0.71 |
| Stochastic Oscillator | 2.96 | 28.82 |
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.